Search
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer.
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab was also granted FDA approval on October 18, 2023.[L48551]
Triflusal
go.drugbank.com/drugs/DB08814ApprovedWithdrawnUriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada.
Stannous fluoride
go.drugbank.com/drugs/DB11092ApprovedInvestigationalIt is an FDA-approved over-the-counter product.
Dimethicone 410
go.drugbank.com/drugs/DB14005Approved[L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigational.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.
Products: Nra-pravastatinEsmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnThe FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.
Alfuzosin
go.drugbank.com/drugs/DB00346Approved[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251]
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198]